Gregory Feldman
Pulmonary Disease · Columbia, SCNPI 1710942305
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,807 of the $72,673 with a category attached, or 64.4%. 47 manufacturers reported payments, led by GSK at 38.4% of the total. Reporting peaked in 2019 at $38,449 and has fallen 99.9% since, to $41 in 2024. Among pulmonary disease clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 773 payments — averaging $94.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$28K
- Mylan Specialty L.p.$19K
- Mylan Inc.$7K
- AstraZeneca$7K
- Sanofi$3K
- Genentech USA, Inc.$2K
- plus $7K from 41 others
Across 3,238 payments — averaging $4661.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$9.8M
- GSK$989K
- Eli Lilly$620K
- AstraZeneca$572K
- Johnson & Johnson$375K
- Merck$313K
- plus $2.4M from 24 others
What the payments were for
- Consulting fees$7,61010%
- Speaking & faculty fees$46,80764%
- Travel & lodging$4,7026%
- Food & beverage$13,46519%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$24,906
- TRELEGY ELLIPTA$21,890
- ANORO$3,722
- DUPIXENT$2,480
- XOLAIR$1,780
- FASENRA$347
- REMODULIN$330
- TYVASO$330
- NONE$330
- FARXIGA$239
- BREZTRI$239
- BEVESPI AEROSPHERE$239
- BREZTRI AEROSPHERE$134
- TEZSPIRE$128
How this compares
$72,673 in reported general payments places this provider in the 90th percentile of 192 pulmonary disease providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $15,542 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $308 |
| Montelukast Sodium | 12 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $27,923 | $15,54223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Columbia
- Richard BoganColumbia$1.1M
- Laura HerpelColumbia$254K
- Jake KriegmdColumbia$112K
- Mark MaysonColumbia$86K
- Karla Cruz MorelColumbia$74K
- Carlton CauthenColumbia$17K
- Liang ZhaColumbia$10K
- Todd GandyColumbia$10K
- Matthew VarnerColumbia$9K
- Abhijit RavalAnderson$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.